WEED, Inc. (BUDZ)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
WEED, Inc. (BUDZ) with AI Score 42/100 (Weak). WEED, Inc. focuses on developing cannabis-derived compounds for treating human diseases. The company, formerly United Mines, Inc. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026WEED, Inc. (BUDZ) Healthcare & Pipeline Overview
WEED, Inc. is a specialty pharmaceutical company focused on the development and application of cannabis-derived compounds for treating human diseases. Operating in the healthcare sector, the company aims to capitalize on the growing market for cannabis-based therapeutics, though it currently faces significant profitability challenges.
Investment Thesis
WEED, Inc. presents a high-risk, high-reward investment opportunity within the cannabis-based pharmaceutical sector. The company's focus on developing cannabis-derived treatments offers potential upside if it can successfully navigate the regulatory landscape and bring viable products to market. However, with a negative profit margin of -2292.8% and a negative gross margin of -9.0%, the company's financial performance raises concerns about its ability to sustain operations. Key catalysts include advancements in its drug development pipeline and potential regulatory changes favoring cannabis-based therapeutics. Investors should carefully weigh the potential for significant growth against the substantial financial and operational risks.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B indicates a micro-cap company with limited resources.
- P/E ratio of -4.01 reflects negative earnings, suggesting the company is currently unprofitable.
- Profit margin of -2292.8% highlights significant operational inefficiencies and challenges in achieving profitability.
- Gross margin of -9.0% indicates that the company's cost of goods sold exceeds its revenue, posing a substantial risk to its financial viability.
- Beta of 0.80 suggests the stock is less volatile than the market average, but this may be due to its limited trading activity.
Competitors & Peers
Strengths
- Focus on cannabis-derived compounds for medical treatments.
- Potential first-mover advantage in specific therapeutic areas.
- Strategic shift towards a growing market segment.
- Low beta suggests relatively stable stock price.
Weaknesses
- Negative profit and gross margins indicate financial instability.
- Small size and limited resources.
- Dependence on regulatory approvals and market acceptance.
- Limited information available on specific products or pipeline.
Catalysts
- Upcoming: Potential advancements in the development of cannabis-derived compounds for treating human diseases.
- Upcoming: Possible regulatory changes favoring cannabis-based therapeutics.
- Upcoming: Strategic partnerships with larger pharmaceutical companies or research institutions.
- Ongoing: Increasing acceptance and legalization of medical cannabis worldwide.
- Ongoing: Research and development efforts to create proprietary formulations.
Risks
- Ongoing: Negative profit and gross margins indicate financial instability.
- Potential: Intense competition from established pharmaceutical companies.
- Potential: Stringent regulatory requirements and evolving regulations.
- Potential: Negative public perception of cannabis.
- Ongoing: Limited financial disclosure and transparency due to OTC listing.
Growth Opportunities
- Expansion into New Therapeutic Areas: WEED, Inc. can explore new therapeutic applications for cannabis-derived compounds beyond its current focus. The market for cannabis-based treatments is expanding, with potential applications in areas such as pain management, mental health, and neurological disorders. Success in developing and commercializing treatments for these conditions could significantly increase the company's revenue and market share. The timeline for this growth opportunity depends on the pace of research and development, as well as regulatory approvals.
- Strategic Partnerships and Collaborations: WEED, Inc. can pursue strategic partnerships with larger pharmaceutical companies or research institutions to accelerate its drug development efforts and access additional resources. Collaborations can provide access to funding, expertise, and distribution channels, increasing the likelihood of successful product development and commercialization. The timeline for this growth opportunity depends on the company's ability to identify and secure suitable partners.
- Geographic Expansion: As regulations surrounding cannabis-based treatments evolve, WEED, Inc. can expand its geographic reach by entering new markets. This could involve establishing operations in countries or regions with favorable regulatory environments or partnering with local distributors to market its products. The timeline for this growth opportunity depends on the pace of regulatory changes and the company's ability to navigate international markets.
- Development of Proprietary Formulations: WEED, Inc. can focus on developing proprietary formulations of cannabis-derived compounds to differentiate its products from competitors. This could involve creating unique delivery systems, optimizing dosages, or combining cannabis compounds with other therapeutic agents. Successful development of proprietary formulations could provide a competitive advantage and increase the company's pricing power. The timeline for this growth opportunity depends on the company's research and development capabilities.
- Capitalizing on the Growing Acceptance of Medical Cannabis: The increasing acceptance and legalization of medical cannabis worldwide presents a significant growth opportunity for WEED, Inc. As more countries and regions legalize medical cannabis, the market for cannabis-based treatments is expected to expand rapidly. WEED, Inc. can capitalize on this trend by developing and commercializing innovative products that meet the needs of patients and healthcare providers. The timeline for this growth opportunity depends on the pace of regulatory changes and the company's ability to adapt to evolving market conditions.
Opportunities
- Expansion into new therapeutic areas and geographic markets.
- Strategic partnerships with larger pharmaceutical companies.
- Increasing acceptance and legalization of medical cannabis.
- Development of proprietary formulations and delivery systems.
Threats
- Intense competition from established pharmaceutical companies.
- Stringent regulatory requirements and evolving regulations.
- Negative public perception of cannabis.
- Potential for product liability claims.
Competitive Advantages
- Proprietary formulations of cannabis-derived compounds (if any).
- Intellectual property protection through patents (if any).
- Strategic partnerships with established pharmaceutical companies (if any).
- First-mover advantage in specific therapeutic areas (if any).
About BUDZ
WEED, Inc., originally incorporated in 1999 as United Mines, Inc., transitioned its focus to the development and application of cannabis-derived compounds in February 2015, adopting the name WEED, Inc. Headquartered in Tucson, Arizona, the company's core business revolves around researching and developing treatments for various human diseases using cannabis-derived compounds. Despite its efforts in the specialty and generic drug manufacturing industry, WEED, Inc. faces significant challenges, as reflected in its negative profit and gross margins. The company's small size, with only two employees, suggests a reliance on external partnerships or a highly focused operational model. Its evolution from United Mines, Inc. indicates a strategic shift to capitalize on the emerging cannabis therapeutics market.
What They Do
- Develop cannabis-derived compounds for medical treatments.
- Research applications of cannabis in treating human diseases.
- Formulate cannabis-based pharmaceuticals.
- Potentially conduct clinical trials to evaluate drug efficacy.
- Seek regulatory approvals for its pharmaceutical products.
- Market and distribute approved cannabis-derived treatments.
Business Model
- Research and development of cannabis-based pharmaceuticals.
- Potential revenue from licensing or selling proprietary formulations.
- Revenue from sales of approved cannabis-derived treatments.
- Partnerships and collaborations with other pharmaceutical companies.
Industry Context
WEED, Inc. operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. The industry is characterized by intense competition, stringent regulatory requirements, and significant research and development costs. The increasing acceptance and legalization of cannabis for medical purposes has created a niche market for companies like WEED, Inc., focusing on cannabis-derived therapeutics. However, the company faces competition from both established pharmaceutical companies and other cannabis-focused businesses. The market is subject to evolving regulations and public perception, adding to the inherent risks.
Key Customers
- Patients seeking alternative treatments for various diseases.
- Healthcare providers recommending cannabis-based therapies.
- Pharmacies dispensing cannabis-derived medications.
- Research institutions collaborating on clinical trials.
Financials
Chart & Info
WEED, Inc. (BUDZ) stock price: Price data unavailable
Latest News
-
Stocks That Fell Through 52-Week Lows Wednesday
· Aug 7, 2019
-
Stocks That Broke Yearly Lows Tuesday Morning
· Aug 6, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BUDZ.
Price Targets
Wall Street price target analysis for BUDZ.
MoonshotScore
What does this score mean?
The MoonshotScore rates BUDZ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Glenn E. Martin
CEO
Glenn E. Martin serves as the CEO of WEED, Inc., leading a small team of two employees. Information regarding his prior professional experience and educational background is not available. As the head of WEED, Inc., Martin is responsible for guiding the company's strategic direction in the development and application of cannabis-derived compounds for the treatment of human diseases. His leadership is crucial for navigating the complex regulatory landscape and driving the company's growth in the emerging cannabis therapeutics market.
Track Record: Due to limited information, Glenn E. Martin's specific achievements and strategic decisions at WEED, Inc. are not available. The company's financial performance, characterized by negative profit and gross margins, suggests significant challenges during his tenure. Further information is needed to assess his track record and contributions to the company's development.
BUDZ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries a higher degree of risk due to the potential for fraud, manipulation, and lack of transparency compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for fraud and manipulation.
- Low trading volume and liquidity.
- High price volatility.
- Lack of regulatory oversight compared to major exchanges.
- Verify the company's legal standing and registration.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal proceedings against the company.
- Company's history of operations since 1999.
- Focus on developing cannabis-derived compounds for medical treatments.
- Change of name to WEED, Inc. in 2015, indicating a strategic shift.
- Headquarters located in Tucson, Arizona.
- Existence of a CEO, Glenn E. Martin, although information is limited.
WEED, Inc. Stock: Key Questions Answered
What does WEED, Inc. do?
WEED, Inc. is a pharmaceutical company focused on the research, development, and potential commercialization of treatments derived from cannabis compounds. The company aims to address various human diseases by leveraging the therapeutic properties of cannabis. While specific products and clinical trial data are limited, the company's core focus is on innovating within the cannabis-based pharmaceutical space, navigating regulatory hurdles, and ultimately bringing novel treatments to market. The company's success hinges on its ability to develop effective and safe cannabis-derived medications.
What do analysts say about BUDZ stock?
Due to the company's OTC listing and limited analyst coverage, there is no readily available consensus view on WEED, Inc.'s stock. Investors should conduct their own thorough due diligence and consider the company's financial performance, business model, and the risks associated with investing in OTC stocks. Key valuation metrics, such as revenue growth and profitability, should be carefully evaluated in light of the company's limited financial disclosure and the inherent uncertainties of the cannabis industry.
What are the main risks for BUDZ?
WEED, Inc. faces several significant risks, including financial instability indicated by negative profit and gross margins. The company operates in a highly regulated and competitive industry, subject to evolving regulations and public perception. As an OTC-listed company, it also faces risks associated with limited financial disclosure, low liquidity, and potential for fraud or manipulation. Investors should carefully consider these risks before investing in WEED, Inc.
What are the key factors to evaluate for BUDZ?
WEED, Inc. (BUDZ) currently holds an AI score of 42/100, indicating low score. Key strength: Focus on cannabis-derived compounds for medical treatments.. Primary risk to monitor: Ongoing: Negative profit and gross margins indicate financial instability.. This is not financial advice.
How frequently does BUDZ data refresh on this page?
BUDZ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BUDZ's recent stock price performance?
Recent price movement in WEED, Inc. (BUDZ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on cannabis-derived compounds for medical treatments.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BUDZ overvalued or undervalued right now?
Determining whether WEED, Inc. (BUDZ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BUDZ?
Before investing in WEED, Inc. (BUDZ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's specific products, clinical trials, and financial performance.
- OTC listing increases the risk of investing in this company.
- AI analysis pending for BUDZ.